Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Wild Type”

112 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 112 results

Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Testing effectiveness (Phase 2)Study completedNCT01075048
What this trial is testing

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Daiichi Sankyo 131
Testing effectiveness (Phase 2)Study completedNCT00885885
What this trial is testing

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Who this might be right for
Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 80
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Testing effectiveness (Phase 2)Ended earlyNCT01186705
What this trial is testing

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Who this might be right for
Colon CancerRectal Cancer
Memorial Sloan Kettering Cancer Center 1
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)UnknownNCT04466254
What this trial is testing

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 75
Testing effectiveness (Phase 2)UnknownNCT01388621
What this trial is testing

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
WiSP Wissenschaftlicher Service Pharma GmbH 140
Testing effectiveness (Phase 2)Study completedNCT00958386
What this trial is testing

Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)

Who this might be right for
Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 61
Testing effectiveness (Phase 2)Study completedNCT01867697
What this trial is testing

Nordic 8 - A Phase II Trial

Who this might be right for
Metastatic Colorectal Cancer
Per Pfeiffer 173
Testing effectiveness (Phase 2)Study completedNCT01443377
What this trial is testing

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Who this might be right for
Rectal Cancer
National Center for Tumor Diseases, Heidelberg 48
Testing effectiveness (Phase 2)Study completedNCT01892527
What this trial is testing

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Who this might be right for
Colorectal Cancer MetastaticC-met Overexpression
Armando Santoro, MD 43
Testing effectiveness (Phase 2)Study completedNCT01308840
What this trial is testing

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Who this might be right for
Biliary Tract CancerGallbladder Cancer
University of Rochester 31
Testing effectiveness (Phase 2)Looking for participantsNCT07257653
What this trial is testing

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsRASBRAF+2 more
Zhejiang University 70
Large-scale testing (Phase 3)Ended earlyNCT01309126
What this trial is testing

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Who this might be right for
Colorectal Cancer
HiberCell, Inc. 217
Large-scale testing (Phase 3)Ended earlyNCT05223673
What this trial is testing

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Recherches Internationales Servier 7
Testing effectiveness (Phase 2)Study completedNCT00778830
What this trial is testing

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

Who this might be right for
Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 289
Testing effectiveness (Phase 2)Study completedNCT01652482
What this trial is testing

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Colorectal Cancer
Genentech, Inc. 135
Testing effectiveness (Phase 2)Study completedNCT01276379
What this trial is testing

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Who this might be right for
Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 221
Testing effectiveness (Phase 2)UnknownNCT02583542
What this trial is testing

AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Who this might be right for
Triple-Negative Breast CancerSquamous Cell Lung CancerNon-squamous Cell Lung Cancer With KRAS Mutations+1 more
Queen Mary University of London 118
Load More Results